Annals of Oncology 15:330-337, 2004
© 2004 European Society for Medical Oncology
Original Paper |
Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study
Received 12 March 2003; revised 28 July 2003; accepted 4 September 2003Background:
Although currently available 5-hydroxytryptamine type 3 receptor (5-HT3) antagonists are effective, not all patients receiving these agents achieve adequate control of chemotherapy-induced nausea and vomiting (CINV). Palonosetron, a potent and highly selective 5-HT3 antagonist with a strong affinity for 5-HT3 and a prolonged plasma elimination half-life, may provide a longer duration of action than other approved agents.
Patients and methods:
One hundred and sixty-one patients were randomly assigned to receive a single intravenous bolus dose of palonosetron (0.3, 1, 3, 10, 30 or 90 µg/kg) before administration of highly emetogenic chemotherapy, with no pretreatment with corticosteroids.
Results:
The four highest doses of palonosetron were similarly effective during the first 24 h, producing clearly higher complete response (CR) (no emesis, no rescue medication) rates in the 3, 10, 30 and 90 µg/kg groups (46%, 40%, 50% and 46%, respectively) than in the 0.3–1 µg/kg group (24%) of evaluable patients (n = 148). The 3 µg/kg dose was identified as the lowest effective dose. A single dose of palonosetron showed prolonged efficacy in preventing delayed emesis, with approximately one-third of patients who received palonosetron 10 or 30 µg/kg maintaining a CR throughout the 7-day period following chemotherapy administration. Dose-proportional increases in pharmacokinetic parameters and a long plasma half-life (43.7–128 h) were observed. Palonosetron was well-tolerated, with no dose–response effect evident for the incidence or intensity of adverse events.
Conclusions:
Palonosetron is an effective and well-tolerated agent for the prevention of CINV following highly emetogenic chemotherapy, with 3 and 10 µg/kg identified as the lowest effective palonosetron doses.
1 California Cancer Care, Greenbrae, CA; 2 VA Medical Center, Reno, NV; 3 Medical College of Wisconsin, Milwaukee, WI; 4 University of California at San Francisco, San Francisco, CA, USA; 5 Helsinn Healthcare SA, Lugano, Switzerland
Key words: chemotherapy, dose-ranging, emesis, 5-hydroxytryptamine type 3 receptor antagonist, nausea, palonosetron
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Maemondo, N. Masuda, I. Sekine, K. Kubota, Y. Segawa, M. Shibuya, F. Imamura, N. Katakami, T. Hida, S. Takeo, et al. A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy Ann. Onc., November 1, 2009; 20(11): 1860 - 1866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Segawa, K. Aogi, K. Inoue, M. Sano, I. Sekine, Y. Tokuda, H. Isobe, T. Ogura, M. Tsuboi, S. Atagi, et al. A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy Ann. Onc., November 1, 2009; 20(11): 1874 - 1880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C. De Jonghe and C. C. Horn Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus) Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R902 - R911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Georgy, J. Neceskas, and S. Goodin Antiemetic care for patients with breast cancer: Focus on drug interactions and safety concerns Am. J. Health Syst. Pharm., November 1, 2007; 64(21): 2227 - 2236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Shah, T. DeGroot, and G. Apseloff Pharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjects. J. Clin. Pharmacol., October 1, 2006; 46(10): 1139 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Aapro, S. Grunberg, G. Manikhas, G Olivares, T Suarez, S. Tjulandin, L. Bertoli, F Yunus, B Morrica, F Lordick, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Ann. Onc., September 1, 2006; 17(9): 1441 - 1449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T Holdsworth and T. Vo-Nguyen Employment of Substandard Antiemetic Prophylaxis in Recent Trials of Chemotherapy-Induced Nausea and Vomiting Ann. Pharmacother., November 1, 2005; 39(11): 1903 - 1910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Hunt, S. C. Gallagher, M. T. Cullen Jr, and A. K. Shah Evaluation of Safety and Pharmacokinetics of Consecutive Multiple-Day Dosing of Palonosetron in Healthy Subjects J. Clin. Pharmacol., May 1, 2005; 45(5): 589 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Constenla 5-HT3 Receptor Antagonists for Prevention of Late Acute-Onset Emesis Ann. Pharmacother., October 1, 2004; 38(10): 1683 - 1691. [Abstract] [Full Text] [PDF]
|
|